These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 21078010)
21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
22. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440 [TBL] [Abstract][Full Text] [Related]
23. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Wohlreich MM; Mallinckrodt CH; Watkin JG; Wilson MG; Greist JH; Delgado PL; Fava M Ann Clin Psychiatry; 2005; 17(4):259-68. PubMed ID: 16402760 [TBL] [Abstract][Full Text] [Related]
24. Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine. Fu CH; Costafreda SG; Sankar A; Adams TM; Rasenick MM; Liu P; Donati R; Maglanoc LA; Horton P; Marangell LB BMC Psychiatry; 2015 Apr; 15():82. PubMed ID: 25880400 [TBL] [Abstract][Full Text] [Related]
26. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Gueorguieva R; Mallinckrodt C; Krystal JH Arch Gen Psychiatry; 2011 Dec; 68(12):1227-37. PubMed ID: 22147842 [TBL] [Abstract][Full Text] [Related]
27. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765 [TBL] [Abstract][Full Text] [Related]
28. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. Joffe H; Soares CN; Petrillo LF; Viguera AC; Somley BL; Koch JK; Cohen LS J Clin Psychiatry; 2007 Jun; 68(6):943-50. PubMed ID: 17592922 [TBL] [Abstract][Full Text] [Related]
29. NGF serum levels variations in major depressed patients receiving duloxetine. Martino M; Rocchi G; Escelsior A; Contini P; Colicchio S; de Berardis D; Amore M; Fornaro P; Fornaro M Psychoneuroendocrinology; 2013 Sep; 38(9):1824-8. PubMed ID: 23507186 [TBL] [Abstract][Full Text] [Related]
30. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410 [TBL] [Abstract][Full Text] [Related]
31. Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study. Karp JF; Weiner DK; Dew MA; Begley A; Miller MD; Reynolds CF Int J Geriatr Psychiatry; 2010 Jun; 25(6):633-42. PubMed ID: 19750557 [TBL] [Abstract][Full Text] [Related]
32. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626 [TBL] [Abstract][Full Text] [Related]
33. Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. Romera I; Pérez V; Menchón JM; Schacht A; Papen R; Neuhauser D; Abbar M; Picard H; Gilaberte I J Affect Disord; 2012 Dec; 143(1-3):47-55. PubMed ID: 22858211 [TBL] [Abstract][Full Text] [Related]
34. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467 [TBL] [Abstract][Full Text] [Related]
35. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Perahia DG; Kajdasz DK; Royer MG; Walker DJ; Raskin J Int Clin Psychopharmacol; 2006 Sep; 21(5):285-95. PubMed ID: 16877900 [TBL] [Abstract][Full Text] [Related]
36. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
37. Duloxetine in the long-term treatment of major depressive disorder. Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974 [TBL] [Abstract][Full Text] [Related]
38. Effects of duloxetine on painful physical symptoms associated with depression. Goldstein DJ; Lu Y; Detke MJ; Hudson J; Iyengar S; Demitrack MA Psychosomatics; 2004; 45(1):17-28. PubMed ID: 14709757 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of duloxetine in patients with chronic low back pain. Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028 [TBL] [Abstract][Full Text] [Related]
40. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]